(Reuters) - Last Wednesday, the company halted further enrollment in this arm of the trial after one patient suffered apparent photo-toxicity, the same side effect reported on Monday.
The company said it was evaluating its options for continuing development of incyclinide in acne at lower doses, as no adverse events were seen there.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment